VTYX Surges 83% After Positive Phase 2 Data for VTX3232.
ByAinvest
Thursday, Oct 23, 2025 3:49 am ET1min read
VTYX--
Shares of Ventyx Biosciences surged 83% after hours on positive Phase 2 data for VTX3232, an oral NLRP3 inhibitor targeting obesity and cardiovascular risk. The drug showed rapid and substantial reductions in inflammation, with hsCRP levels dropping 80% within the first week and IL-6 levels falling below the cardiovascular risk threshold by Week 12. The company reported strong safety and tolerability, with no impact on weight in both monotherapy and combination arms.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet